Ensysce Biosciences Inc.

97 articles about Ensysce Biosciences Inc.

• Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

  4/19/2024

  Ensysce Biosciences, Inc. today announced the Company's webcast presentation and discussion during the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17, 2024 is available on Ensysce's Investor Relations website at ir.ensysce.com and can also be viewed here.

• Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

  3/15/2024

  Ensysce Biosciences, Inc. today reported financial results for the fourth quarter and full year of 2023.

• Ensysce Biosciences Receives Positive Nasdaq Listing Determination - February 27, 2024

  2/27/2024

  Ensysce Biosciences, Inc. today announced that it has received notice from The Nasdaq Stock Market LLC as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024.

• Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

  2/21/2024

  Ensysce Biosciences, Inc. is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, 'Next Generation' opioid analgesic with overdose protection, PF614-MPAR.

• Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

  2/15/2024

  Ensysce Biosciences, Inc. announced online publication of its manuscript entitled, "Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin® in a multi-ascending dose study with a bioequivalence arm in healthy volunteers" published online by the open-access medical journal Clinical and Translational Science sponsored by the American Society of Clinical Pharmacology and Therapeutics.

• Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

  2/13/2024

  Ensysce Biosciences, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock.

• Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

  1/31/2024

  Ensysce Biosciences, Inc. today announced the completion of a constructive End of Phase 2 meeting with the Food and Drug Administration (FDA) regarding its lead Next Generation analgesic, PF614.

• 

  Promising Vertex Pain Med Points to New Era for Analgesics

  1/30/2024

  While some biopharma companies seek an effective and non-addictive alternative to opioids, others are looking to make opioids themselves safer.

• Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

  12/19/2023

  Ensysce Biosciences, Inc., announced that the Company's Special Meeting of Stockholders to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to lack of the required quorum.

• Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

  12/14/2023

  Ensysce Biosciences, Inc., a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced that its most recent study has demonstrated crucially important data for PF614 on pain intensity efficacy and speed of onset.

• Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

  11/28/2023

  Ensysce Biosciences, Inc. and OncoZenge AB are pleased to announce that they have signed a letter of intent to explore a strategic collaboration to accelerate the commercialization of BupiZenge™ in the United States.

• Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

  11/16/2023

  Ensysce Biosciences, Inc. today announced that the PF614-201 study, & A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy Male Subjects' has completed enrollment.

• Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

  10/24/2023

  Ensysce Biosciences, Inc. announced today that it has entered into a securities purchase agreement with investors in the form of senior secured convertible notes.

• Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

  10/18/2023

  Ensysce Biosciences, Inc. today announced Dr. Dolly Jacob, Director Integrated Development Services of Quotient Sciences, will present the collaborative work of Ensysce and Quotient Sciences in a poster.

• Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Ensysce Biosciences, Inc. today announced that its management has been invited to present at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York, NY on September 11-13, 2023.

• Ensysce Biosciences Reports Second Quarter 2023 Financial Results

  8/11/2023

  Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023.

• Ensysce Biosciences Announces IRB Approval of Key Study Protocol

  8/8/2023

  Ensysce Biosciences, Inc. today announced the Investigational Review Board approval of PF614-201 protocol.

• Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

  6/27/2023

  Ensysce Biosciences, Inc. today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release Society) 2023 Annual Meeting & Expo.

• Ensysce Biosciences to Participate in Upcoming Industry Events

  6/6/2023

  Ensysce Biosciences, Inc. today announced two upcoming presentations in June. Chief Medical Officer, Dr. Bill Schmidt, will present in The College on Problems of Drug Dependence (CPDD) 85th Annual Scientific Meeting in Denver, CO, on June 17-21, 2023.

• 

  Opinion: What to Expect From an Experimental Anti-Abuse Opioid Drug

  5/30/2023

  Although still in early-stage testing, Ensysce Biosciences’ formulation has demonstrated the potential to address addiction problems associated with oral oxycodone.